Our study demonstrated DHTS as a novel therapeutic agent of ovarian cancer, which disrupts PI3K pathway, and sensitizes cancer cells to platinum by inducing more DNA double‐strand breaks (DSBs). This evidence concerns the gene PIK3CA and cancer.